AZD1163

DRUG4 trials

Sponsors

AstraZeneca AB, AstraZeneca, AstraZeneca Pharmaceuticals Pty LTD

Conditions

Healthy VolunteersMusculoskeletal DiseasesRheumatoid ArthritisRheumatoid arthritis

Phase 1

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

CompletedNCT06103877

AstraZenecaHealthy Volunteers

Start: 2023-11-01End: 2026-01-13Updated: 2026-01-27

Phase 2

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

RecruitingNCT07276581

AstraZenecaRheumatoid Arthritis

Start: 2025-12-15End: 2028-08-18Target: 320Updated: 2026-06-24

A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

Not yet recruitingCTIS2025-522076-85-00

AstraZeneca ABRheumatoid arthritis

Target: 78Updated: 2026-04-23

A Multicentre, Parallel-group, Phase II, Randomised, Double blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants with Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

Active, not recruitingPACTR202606808135933

AstraZeneca Pharmaceuticals Pty LTDMusculoskeletal Diseases

Start: 2026-06-01Target: 320Updated: 2026-08-03